Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q3 FY26 Earnings Presentation
16 slides from Zydus Lifesciences's earnings presentation, Feb 9, 2026
Slide 1: Exchange filing cover letter for investor presentation
February 9, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Ref.: Disclosure
Slide 2: Earnings Presentation: Q3 & 9M FY26
Zydus Lifesciences Limited Earnings Presentation: Q3 & 9M FY26 9 th February 2026 1
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”) . The material that follows is a Presentation of genera
Slide 4: Q3 FY26: At a Glance
Q3 FY26: At a Glance Revenues from Highlights of Q3 FY26 R&D Operations ❑ Total revenues registered robust 30% YoY growth. Rs. 68,645 mn Rs. 6,074 mn ❑ Within Pharmaceutical business, 30% YoY 8.8% of revenues ➢ India branded formulations sustained the growth momentum and outpaced the market growth f
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 68,645 69.9 % 74.0 % 72.8 % 72.4 % 73.2% 65,279 65,737 61,232 50,282 48,308 47,842 52,691 44,327 36,857 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Total R&D (Rs. mn) and
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) PAT ex. Exceptional (Rs. mn) Organic Capex (Rs. mn) 4,911 14,668 4,637 13,905 12,863 4,020 11,109 10,235 3,202 2,907 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q3 FY25 Q4 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Net Debt to EBITDA (x) Net Working Capital* (Rs. mn) 0.36 75,938 0.30 72,51
Slide 7: India Formulations business
India Formulations business Sustained market outperformance driven by chronic portfolio Highlights for the quarter India Formulations Sales (Rs. mn) Q3 FY26 Revenue 17,094 ▪ Branded business outpaced IPM growth with 14% YoY Contribution 15,145 15,394 15,195 15,926 growth led by sustained traction in
Slide 8: North America Formulations business
North America Formulations business Sustained growth through execution excellence Highlights for the quarter North America Formulations Sales (Rs. mn) Q3 FY26 Revenue US Generics Contribution 31,307 31,817 ▪ 4 new launches, 8 ANDA approvals (incl. 4 tentative 27,437 28,043 24,096 approvals ) and 18
Slide 9: International Markets Formulations business
International Markets Formulations business Strong growth driven by robust execution across markets Highlights for the quarter IM Formulations Sales (Rs. mn) Q3 FY26 Revenue Contribution 7,265 7,513 7,881 ▪ Growth was broad based across regions, driven by strong demand and focused execution. 5,702 5
Slide 10: Consumer Wellness
Consumer Wellness Expanded international presence through CCL acquisition Dominant market share across key brands Consumer Wellness Sales (Rs. mn) Q3 FY26 Revenue 9,578 Contribution 9,081 Brand Name Mkt Share % Mkt Rank 8,549 6,374 33.1% * 1* 4,488 14% Facial Cleansing # 7.9% * 5* Scrub 48.5% * 1* Q
Slide 11: Updates on Innovation
Updates on Innovation NCE Research – Saroglitazar Magnesium • Preparing to file an NDA of the molecule with the USFDA during the current quarter . Biotech R&D • Received regulatory approval to initiate Phase III clinical trials of the second biosimilar ADC in India . Vaccines R&D • Initiated Phase I
Slide 12: Zydus at a Glance
Zydus at a Glance ~$2.75 R&D Centers bn Global Revenues 1 3 rd Largest generic Co. in US in terms of prescription 3 8 For NCE, APIs, Generics, Vaccines Biosimilars, Wellness and Med -tech products Revenues from Branded Among Approved product for >50% Business (Pharmaceutical, Wellness and Med -Tech)
Slide 13: ESG Updates
ESG Updates 2023 2024 2025 62 78 84 Higher the Better Corporate Sustainability Assessment by S&P Global ESG Score 2025: ➢ Ranks among Top 3 in the Global Drug & Pharmaceutical Sector of S&P Global Universe. ➢ 35% improvement in ESG score over the last 3 years. 2025 Higher the Better Zydus Lifescienc
Slide 14: Consolidated Financial Performance
Consolidated Financial Performance Q3 Q3 YoY Q2 QoQ 9M 9M YoY Rs. mn FY26 FY25 gr. FY26 gr. FY26 FY25 gr. Total Income from Ops. 68,645 52,691 30.3% 61,232 12.1% 1,95,614 1,67,136 17.0% Gross Contribution (GC) 50,282 36,857 36.4% 44,327 13.4% 1,42,451 1,20,727 18.0% Gross Margin % 73.2% 69.9% 72.4%
Slide 15: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q3 Q3 YoY 9M 9M YoY Rs. mn FY26 FY25 gr. % FY26 FY25 gr. % A. On operating transactions (above EBITDA line) -1,649 -1,776 7.1% -5,924 -1,966 -201.3% a. Included in COGS -5 62 -108% 432 73 492.6% b. Part of other operating expenses (shown separately) -1,644 -1,82
Slide 16: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-22 -62711905 For more information, please visit: www.zyduslife.com Registered Office: www.linkedin.com/company/zyduslife Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi